Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00743119 · ClinicalTrials.gov registry record · Phase 2

Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers

A Phase 2 study, sponsored by New York State Psychiatric Institute.

Completed
Registry status
Phase 2
Development phase
34
Enrollment target

NCT00743119: Completed Phase 2 study, sponsored by New York State Psychiatric Institute.

NCT00743119 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00743119, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.

COMPLETED
Registry status
Phase 2
Development phase
34 participants
Enrollment target

Study Summary

The following study is designed to determine the analgesic efficacy of smoked marijuana (0, 1.98, and 3.56% THC) and oral THC (0, 10, and 20 mg) in the Cold-Pressor Test (CPT), a laboratory model of pain which has predictive validity for clinical use of analgesics. Oral THC (dronabinol) is known to have a slower onset and longer duration of action compared with smoked marijuana. Therefore, the analgesic effects of oral THC is expected to peak later and last longer than effects produced by smoked marijuana.

Primary Outcome

Change in pain tolerance from baseline (in seconds) as a function of drug condition. The cold pressor test was administered during each session to examine changes in pain threshold (how many seconds it takes for a participant to begin feeling pain after cold water immersion).

Interventions

  • DRUG Placebo capsules
  • DRUG Inactive marijuana (0% THC)
  • DRUG Low dose Dronabinol
  • DRUG High dose Dronabinol
  • DRUG Low THC marijuana

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2008-06
Est. Completion 2013-05
Phase Phase 2

What the finished NCT00743119 record still lists

NCT00743119 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).

The record links to 0 conditions, and to 5 interventions - of which Placebo capsules is the first listed.

NCT00743119 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00743119 about?

NCT00743119 is a clinical study titled "Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers". The following study is designed to determine the analgesic efficacy of smoked marijuana (0, 1.98, and 3.56% THC) and oral THC (0, 10, and 20 mg) in the Cold-Pressor Test (CPT), a laboratory model of pain which has predictive validity for clinical use of analgesics. Oral THC (dronabinol) is known to ...

What is the current status of trial NCT00743119?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2008-06. Estimated completion is 2013-05.

What interventions are being tested in trial NCT00743119?

The interventions under investigation include: Placebo capsules (DRUG), Inactive marijuana (0% THC) (DRUG), Low dose Dronabinol (DRUG), High dose Dronabinol (DRUG), Low THC marijuana (DRUG).

Who is sponsoring clinical trial NCT00743119?

This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00743119's enrollment target sits among peer trials

34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00743119, the US trial registry maintained by the National Library of Medicine. NCT00743119 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.